John Oyler, BeiGene CEO (Endpoints News, PharmCube)
BeiGene gets the ball rolling on its 3rd IPO — and this one is expected to fetch $3B
BeiGene was among the first China-based biotech companies to list on Nasdaq and made history by raising $903 million in its secondary listing in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
